Theragnostics Ltd   Report issue

For profit Phase 2
Founded: Berkshire United Kingdom (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2018
NCT03617588
First Marketed Drug
2022
succimer (Chemet)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

THERAGNOSTICS | Theragnostics Ltd

Active Ingredients

Marketed Drugs (1)

succimer (Chemet) (2022)

Drugs in Phase 2 Trials (1)

Ga 68 PSMA-11 (Illuccix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 2)

Recurrence (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1